An update on non-peptide angiotensin receptor antagonists and related RAAS modulators

Life Sciences
G K AulakhManjeet Singh


The renin-angiotensin-aldosterone-system (RAAS) is an important regulator of blood pressure and fluid-electrolyte homeostasis. RAAS has been implicated in pathogenesis of hypertension, congestive heart failure, and chronic renal failure. Aliskiren is the first non-peptide orally active renin inhibitor approved by FDA. Angiotensin Converting Enzyme (ACE) Inhibitors are associated with frequent side effects such as cough and angio-oedema. Recently, the role of ACE2 and neutral endopeptidase (NEP) in the formation of an important active metabolite/mediator of RAAS, ang 1-7, has initiated attempts towards development of ACE2 inhibitors and combined ACE/NEP inhibitors. Furukawa and colleagues developed a series of low molecular weight nonpeptide imidazole analogues that possess weak but selective, competitive AT1 receptor blocking property. Till date, many compounds have exhibited promising AT1 blocking activity which cause a more complete RAAS blockade than ACE inhibitors. Many have reached the market for alternative treatment of hypertension, heart failure and diabetic nephropathy in ACE inhibitor intolerant patients and still more are waiting in the queue. But, the hallmark of this area of drug research is marked by a progress in...Continue Reading


Mar 27, 1975·The New England Journal of Medicine·D H StreetenT G Dalakos
Aug 22, 1977·JAMA : the Journal of the American Medical Association·H GavrasI Gavras
Jul 21, 1992·European Journal of Pharmacology·J ZhangJ C Van Meel
Apr 1, 1991·Hypertension·N E RhalebD Regoli
Nov 11, 1991·Hypertension·P B TimmermansA L Johnson
Jan 1, 1991·Advances in Pharmacology·H D KleinertH H Stein
May 31, 1991·Biochemical and Biophysical Research Communications·A T ChiuP B Timmermans
Jan 1, 1989·Cardiology·J NussbergerH R Brunner
Aug 30, 1989·Biochemical and Biophysical Research Communications·S WhitebreadM de Gasparo
Nov 15, 1988·European Journal of Pharmacology·A T ChiuP B Timmermans
May 30, 1985·The New England Journal of Medicine·J A LuetscherM Bryer-Ash
Apr 28, 1995·European Journal of Pharmacology·M FleschA Sachinidis
Jan 1, 1995·Journal of Cardiovascular Pharmacology·S MochizukiA Tomiyama
May 1, 1995·Hypertension·M de GasparoP B Timmermans
Apr 1, 1995·Kidney International·S ShanmugamC M Llorens-Cortes
Oct 1, 1994·Trends in Pharmacological Sciences·M J RobertsonP Leff
Jan 1, 1994·Current Opinion in Nephrology and Hypertension·R D Smith, P B Timmermans
Jan 1, 1994·British Journal of Pharmacology·A HilditchM J Robertson
Dec 10, 1993·Journal of Medicinal Chemistry·M K VanAttenP B Timmermans
Oct 16, 1995·European Journal of Pharmacology·M MizunoH Koike
Aug 30, 1996·Molecular and Cellular Endocrinology·S MeffertT Unger
Jan 1, 1997·Clinical Pharmacokinetics·C CsajkaJ Biollaz
Dec 5, 1997·Journal of Cardiovascular Pharmacology·K TamuraK Hashimoto
Apr 1, 1995·Molecular Medicine Today·G P VinsonJ R Puddefoot
May 20, 1998·Drugs·K J McClellan, J A Balfour
Sep 12, 1998·Lancet·J NussbergerA Agostoni

❮ Previous
Next ❯


Nov 26, 2009·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Siegtraut Dorothea HerderHartmut Morck
Jan 25, 2013·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Jeong Bae ParkEun Joo Cho
Oct 5, 2013·Journal of Chemical Information and Modeling·Minos-Timotheos MatsoukasTheodore Tselios
Oct 12, 2012·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Daisuke UenoHironobu Yoshimatsu
Jan 9, 2010·Annual Review of Pharmacology and Toxicology·Michael Bader
Jul 3, 2013·Biological & Pharmaceutical Bulletin·Yong Ha ChiKyung-Tae Lee
Dec 24, 2011·Journal of the American Society of Nephrology : JASN·Dong LiAnita Aperia
Feb 21, 2009·Journal of Periodontology·C F SantosM C O Salgado
Dec 5, 2015·The Journal of Organic Chemistry·Alexei V Buevich
Mar 19, 2016·Journal of the American Chemical Society·Tejas K ShahNeil K Garg
Apr 1, 2014·Neuroscience Letters·Junjun LiuHiroto Komano
Jul 1, 2014·Clinical and Experimental Nephrology·Takako NagaiKeizo Kanasaki
Jul 14, 2017·Organic Letters·Giovanni Di MauroNuno Maulide
May 22, 2009·Expert Opinion on Therapeutic Patents·David W Laight
Dec 4, 2009·Expert Review of Cardiovascular Therapy·Yves LacourcièreRita Samuel
Aug 25, 2017·Expert Opinion on Investigational Drugs·Santiago Perez-LloretFrancisco Capani
Jan 25, 2021·Drug Discovery Today·Antonio VitielloFrancesco Ferrara
Mar 9, 2021·The Journal of Organic Chemistry·Andrea M NikolićIgor M Opsenica
Dec 2, 2017·Journal of Chemical Information and Modeling·Khuraijam Dhanachandra SinghSadashiva S Karnik
Nov 13, 2010·Bioorganic & Medicinal Chemistry·Prashant NaikMange Ram Yadav

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Ataxia telangiectasia (MDS)

Ataxia telangiectasia is a rare neurodegenerative diseases caused by defects in the ATM gene, which is involved in DNA damage recognition and repair pathways. Here is the latest research on this autosomal recessive disease.


Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.


Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.


Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis


Cardiomegaly, known as an enlarged heart, is a multifactorial disease with different pathophysiological mechanisms. Hypertension, pregnancy, exercise-induced and idiopathic causes are some mechanisms of cardiomegaly. Discover the latest research of cardiomegaly here.

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.